Furthermore, AOD-9604 has shown promise in promoting cartilage repair, reducing inflammation, and improving joint health, broadening its potential therapeutic applications
longer cycles raise copper-accumulation concern from GHK-Cu
Disclosure of interest: Lino Braadt: nothing to disclose, Markus Naumann: nothing to disclose, Dennis Freuer: nothing to disclose, Christa Meisinger: nothing to disclose, Jakob Linseisen: nothing to disclose, Michael Ertl: nothing to disclose Scientific Communications: atherosclerosis and stroke 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.04 - STROKE COMPLICATIONS O - ESOC25-536 SAFETY AND EFFICACY OF DRUG-COATED BALLOON IN PATIENTS WITH SEVERE VERTEBRAL ARTERY ORIGIN STENOSIS (DCB-VAOS): A MULTICENTRE RANDOMISED TRIAL Liqun Jiao 1 , Yabing Wang 1 , Tao Wang 1,1 , Jichang Luo 1 , Rixuan Peng 1 , Changchun Jiang 2 , Haibo Wang 3 1 The Departments of Neurosurgery and Interventional Neuroradiology, Beijing, China, 2 Department of Neurology, Inner Mongolia Autonomous Region, China, 3 Peking University Clinical Research Institute, Beijing, China Background and Aims: Restenosis post endovascular treatment of vertebral artery origin stenosis (VAOS), with/without a bare-metal stent (BMS) and linked to recurrent stroke/death, is high compared to other vascular lesions
Theoretical risks of sustained angiogenic stimulation (promoting vascular supply to undetected pathological tissue) grow proportionally with the duration of use, as cumulative VEGF upregulation exceeds the controlled, injury-localized window intended by short-cycle research protocols
